DAC
Indication: Multiple Sclerosis
Daclizumab PK simulator. Daclizumab is a humanized IgG1 monoclonal antibody that binds CD25 (IL-2 receptor alpha subunit), blocking IL-2 signaling to activated T cells. Used in relapsing multiple sclerosis. Simulate concentration-time profiles for IV and SC dosing regimens.
Drug Overview
Clinical Context
- Molecular Target
- CD25 (IL-2 receptor alpha)
- Drug Class
- Monoclonal Antibody (Anti-CD25)
- Therapeutic Area
- Neurology
- Indication
- Multiple Sclerosis
- Route of Administration
- IV/SC
Model Information
- Model Type
- 2-Cpt DAC PK + PROTAC release + protein degradation + tumor PD
- Category
- PopPK
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
Pharmacokinetic Parameters
PD Parameters
| Parameter | Value |
|---|---|
| DC50 | 1.0 nM |
| Dmax | 95% |
Additional Parameters
| Parameter | Value |
|---|---|
| DAR | 4.0 |
| kng | 0.01 h-1 |
| kmax | 0.05 h-1 |
Parameters sourced from published population pharmacokinetic models. Values represent typical population estimates; individual patient parameters may vary.
About This Simulator
This interactive pharmacokinetic simulator for DAC allows you to explore concentration-time profiles under different dosing scenarios. The underlying PopPK model characterizes the pharmacokinetics of this monoclonal antibody (anti-cd25) following iv/sc administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the DAC PK simulator?
This is a free, interactive pharmacokinetic simulator for DAC used in Multiple Sclerosis. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does DAC belong to?
DAC is classified as a Monoclonal Antibody (Anti-CD25) that targets CD25 (IL-2 receptor alpha). It is used in the Neurology therapeutic area.
What route of administration does this model simulate?
This simulator models IV/SC administration of DAC. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a PopPK model. Population PK models account for interindividual variability and covariate effects on drug exposure.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Ready to Simulate?
Launch the DAC simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community